bioRxiv Science⌕ Search

Biology subjects

Letovanec, I.

Publications and source records attributed to Letovanec, I..

3 recordsLinked to original sources

Extended pre-training of histopathology foundation models uncovers co-existing breast cancer archetypes characterized by RNA splicing or TGF-β dysregulation

In recent years, histopathology foundation models (hFM) have rapidly advanced in size and complexity, achieving excellent performance in tasks such as cancer diagnosis and biomarker discovery. Here, we reveal novel capabilities of these models by specializing hFMs, originally trained on diverse tissue types, specifically to invasive tumor tissue. It enables unprecedented discrimination of visually similar yet molecularly distinct tumor regions, that were previously indistinguishable by baseline models, which eventually leads to uncovering new biological insights into breast cancer. Our contributions are threefold. First, to the best of our knowledge, this is the first study to systematically evaluate the biological concepts encoded within hFM representations across multiple scales. Second, we explore extended pre-training to identify optimal conditions that enhance the models ability to encode richer, tumor tissue-specific biological concepts. We show that this refinement strategy transforms generalist models into a specialist one capable of resolving subtle, recurrent tumor regions with distinct morphological and molecular identities, called tumor archetypes. Finally, leveraging this specialized model, we uncover two dominant tumor archetypes in invasive breast cancer characterized by distinct aberrant gene expression signatures, notably RNA metabolism dysregulation and TGF-{beta} signaling. Strikingly, these archetypes coexist within the same tumors as spatially distinct regions with varying densities and patterns, and are recurrent across patients, highlighting their universality and potential clinical relevance for patient stratification. Altogether our study demonstrates how extended pre-training of state-of-the-art hFM with specific tumor tissues can unlock rich molecular and morphological information encoded in H&E images. By providing a more accessible approach to investigating tumor heterogeneity, this work opens new avenues for precision oncology, using routine histopathology slides and low computational resources. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=128 SRC="FIGDIR/small/645192v1_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@38e660org.highwire.dtl.DTLVardef@19ce335org.highwire.dtl.DTLVardef@108e8e6org.highwire.dtl.DTLVardef@1f25bc0_HPS_FORMAT_FIGEXP M_FIG Graphical abstract C_FIG

cancer biology↗

Patient-derived lymphomoids preserve the tumor architecture and allow to assess response to therapies in lymphoma

The efficacy of anti-cancer therapies depends on the genomic composition of the tumor, its microenvironment, spatial organization, and intra-tumor heterogeneity. B cell lymphomas are a heterogeneous group of tumors emerging from B cells at different stages of differentiation and exhibiting tumor-specific interactions with the tumor microenvironment. Thus, to measure response to therapy in lymphoma, it is critical to preserve the tumor composition and functional interactions among immune cells. Here, we developed a platform to maintain small fragments of human lymphoma tissue in culture for several days and use them to test response to therapies. We collected 25 patient samples representative of different lymphoma subtypes and established ex vivo tissue fragments that retained histological, cellular, and molecular characteristics of the original tissue, here referred to as lymphomoids. Using lymphomoids, we tested sensitivity to several clinically approved small molecule inhibitors in parallel and examined tissue remodeling upon treatment. Importantly, when this information was available, we showed that sensitivity to therapy observed in lymphomoids was consistent with patients response in the clinic. Lymphomoids are an innovative tool to assess treatment efficacy in clinically relevant contexts and could be used to uncover novel aspects of lymphoma biology.

cancer biology↗

Opposing immune and genetic forces shape oncogenic programs in synovial sarcoma

Synovial sarcoma is an aggressive mesenchymal neoplasm, driven by the SS18-SSX fusion, and characterized by immunogenic antigens expression and exceptionally low T cell infiltration levels. To study the cancer-immune interplay in this disease, we profiled 16,872 cells from 12 human synovial sarcoma tumors using single-cell RNA-sequencing (scRNA-Seq). Synovial sarcoma manifests antitumor immunity, high cellular plasticity and a core oncogenic program, which is predictive of low immune levels and poor clinical outcomes. Using genetic and pharmacological perturbations, we demonstrate that the program is controlled by the SS18-SSX driver and repressed by cytokines secreted by macrophages and T cells in the tumor microenvironment. Network modeling predicted that SS18-SSX promotes the program through HDAC1 and CDK6. Indeed, the combination of HDAC and CDK4/6 inhibitors represses the program, induces immunogenic cell states, and selectively targets synovial sarcoma cells. Our study demonstrates that immune evasion, cellular plasticity, and cell cycle are co-regulated and can be co-targeted in synovial sarcoma and potentially in other malignancies.

cancer biology↗